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Pressing Forward: Connecticut's
Approach to Embryonic Stem Cell
Research
Rebekah L. Baileyt
This is big. This is not a wedge issue .... This is... who we
are as a country and how we feel about our people and about
the majority ... respecting the minority.'
If the potential of stem cell research is realized, it would mean
an end to the suffering of millions of people-a rescue, a cure.
. . . Stem cells could lead to breakthroughs in developing
treatments and cures for almost any terminal or catastrophic
disease you can think of. This is one of the reasons that
support for this work has galvanized a coalition of advocates
from just about every patient community in the nation. If
stem cell research succeeds, there isn't a person in the country
who won't benefit, or know somebody who will. 2
- Michael J. Fox
Introduction
For many Americans, embryonic stem cell research ("ESCR")
provides hope for the treatment of debilitating diseases and
disabilities, such as leukemia, immune deficiencies, diabetes, liver
disease, cardiovascular disease, neurological disorders,
Alzheimer's disease, Parkinson's disease, spinal cord trauma, and
cancer. 3 Although the technology is still young, many scientists
share in this optimism. 4 New advancements are reported almost
t. J.D. expected 2008, University of Minnesota Law School; B.S. 2004, Grand
Valley State University. The author would like to thank the Board and Staff of
Law and Inequality: A Journal of Theory and Practice for all their hard work and
her family for all their love and support. This Article is dedicated to her father,
who is patiently waiting.
1. Interview by Katie Couric with Michael J. Fox, in New York, N.Y., Oct. 26,
2006, available at http://www.cbsnews.com/stories/2006/10/26/eveningnews/
main2129702.shtml.
2. MICHAEL J. Fox, LuCKY MAN 152 (2002).
3. JOSEPH PANNO, STEM CELL RESEARCH: MEDICAL APPLICATIONS AND
ETHICAL CONTROVERSY 35-49 (2005); JENNIFER VIEGAS, STEM CELL RESEARCH 56
(2003).
4. Thomas B. O'Karma, Human Embryonic Stem Cells: A Primer on the
Technology and Its Medical Applications, in THE HuMAN EMBRYONIC STEM CELL
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daily. 5
Yet other Americans consider this surreal research immoral
because it involves the destruction of embryos. 6 Embryos and
other fetal tissue have been destroyed in pursuit of research since
long before the provocative debate over stem cell research ("SCR")
began. 7 Before Roe v. Wade,8 fetal research was not met with
large scale hostility. Post-Roe, opposition to fetal research
extended to ESCR, but not to alternative reproductive
technologies. 9  This selective opposition creates an irrational
distinction between two methods of research that destroy embryos
at similar stages of gestation.
The federal government currently agrees with research
opponents who argue that the potential life harbored within
embryos should be protected. 10 In 2001, the federal government
implemented an embryo-friendly policy, restricting the type of
SCR eligible for federal government funding.'1 Unfortunately,
this approach has severely hindered the progress of American
scientists, dashing the hopes of millions who await cures for their
debilitating diseases and injuries.12 Since the implementation of
this policy, Congress has tried and failed on a few occasions to
lessen the restrictions on federally funded research. 13
Both the fear of losing top scientists and the potential for
developing a niche economic market in human ESCR have enticed
a handful of states to reconsider their anti-research policies.14 In
DEBATE: SCIENCE, ETHICS, AND PUBLIC POLICY 3, 5-6 (Susan Holland et al. eds.,
2002).
5. Id.
6. Lydia Saad, Americans Rate the Morality of 16 Social Issues, GALLUP POLL
BRIEFING, June 4, 2007.
7. 1 NAT'L BIOETHICs ADVISORY COMM'N, ETHICAL ISSUES IN HUMAN STEM
CELL RESEARCH: REPORT AND RECOMMENDATIONS OF THE NATIONAL BIOETHICS
ADVISORY COMMISSION 29 (1999), available at http://bioethics.georgetown.edul
nbac/stemcell.pdf.
8. 410 U.S. 113 (1973).
9. PANNO, supra note 3, at 78.
10. President George W. Bush, Speech on Stem Cell Research in Crawford, Tex.
(Aug. 9, 2001), in LORI B. ANDREWS ET AL., GENETICS: ETHICS, LAW AND PUBLIC
POLICY 141 (2002), available at http://www.whitehouse.gov/news/
releases/2001/08/20010809-2.html (last visited Oct. 27, 2007) [hereinafter President
Discusses Stem Cell Research].
11. See id.
12. See Heather L. Fowler, Misapplied Ethical Considerations: U.S. Federal
Stem Cell Mandates Lack Global Focus and Market Foresight, 36 CORNELL INT'L
L.J. 521, 523 (2004).
13. See, e.g., Stem Cell Research Enhancement Act of 2005, H.R. 810, 109th
Cong. (2005); infra text accompanying notes 128-140.
14. EVE HEROLD, STEM CELL WARS: INSIDE STORIES FROM THE FRONT LINES 152
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an effort to compensate for the lack of federal funding, some states
have begun to either pool together private and public research
funds or construct new scientific institutes. 15 Some have also
adopted regulatory requirements to ensure this research complies
with generally accepted rules of bioethics. 16 While few states have
successfully implemented their plans, at least one state thus far
has produced and implemented a promising policy. 17
Through examining Connecticut's approach to ESCR in
comparison with the current federal policy, this Note explores the
role of law in a newly emerging scientific field. Part I illustrates
this rapidly advancing technology, the potential benefits it may
provide, and the controversy it creates. Part II points to
unfriendly political and legal precedent as a possible explanation
for American hostility towards research. Part III and Part IV
describe, respectively, the federal government and a majority of
the states have enacted policies that further inhibit technological
progress, although some states have recently enacted supportive
legislation. In comparison, Part V explores Connecticut's carefully
crafted scientific definitions, explicitly defined regulatory
committees, broad authorization of progressive research methods,
and responsible distribution of public funds. Finally, Part VI
urges Americans to consider all the wonderful possibilities for
ESCR. Connecticut's ESCR policy is one that should be emulated
by states seeking to join in the cause of alleviating the suffering of
millions of Americans.
I. Understanding the Controversial Technology
The first successfully isolated stem cells were extracted from
mouse embryos in 1981;18 however, it was not until 1998 that two
teams of scientists isolated human stem cells. 19 One group of
researchers, headed by Dr. John Gearhart of Johns Hopkins
University, extracted embryonic germ cells 20 from a fetus aborted
between approximately the second and fourth month of
gestation. 21 That same year, Dr. James Thomson, along with his
(2006).
15. Id. at 145-49.
16. Id. at 152.
17. See infra Part V.
18. VIEGAS, supra note 3, at 42.
19. Id. at 45; PANNO, supra note 3, at 18.
20. Embryonic germ cells are reproductive cells derived from a fetus at five to
ten weeks of gestation that later form either the sperm or the eggs of the fetus.
VIEGAS, supra note 3, at 27.
21. PANNO, supra note 3, at 19-20.
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team at the University of Wisconsin-Madison, extracted embryonic
stem cells ("ESCs") from a discarded blastocyst obtained from an
in vitro fertilization ("IVF') clinic. 22
A blastocyst is a zygote as it appears five to six days after a
sperm fuses with an egg. 23 It is comprised of approximately one
hundred cells collectively and is no larger than a period on this
page. 24 Scientists disagree as to whether or not a blastocyst
should be identified as an "embryo" because not all of the cells in a
blastocyst continue on to form a fetus. 25 Instead, some of the cells
later become the placenta or umbilical cord. 26 Because not all cells
in a blastocyst are slated to become potential life, some scientists
prefer to label the group of cells at this stage of development as
"preimplantation" embryos or "preembryos." 27
Even the cells expected to form the fetus do not always
succeed in their mission. 28 Once in utero, a blastocyst takes
approximately one week to attach to the womb, or it fails trying.29
Seventy-five percent of blastocysts never attach to later become
fetuses.30 In some instances, more than one blastocyst attach to
the uterus lining concurrently. 31 This occurrence can produce
multiple fetuses, but it is equally as likely that some of the
attached blastocysts "dissolve" or are subsumed into the surviving
embryo. 32  Successfully attached blastocysts multiply into
approximately two hundred cells by the fourteenth day of
formation, and then they begin to differentiate. 33 Differentiation
is the process whereby an unspecialized early embryonic cell
22. Id. at 19; see also VIEGAS, supra note 3, at 45.
23. PANNO, supra note 3, at 77.
24. Id.
25. Fowler, supra note 12, at 533. The trophoblast, part of the blastocyst, later
becomes the placenta and umbilical cord, while the inner cell mass of the blastocyst
goes on to form the embryo. Those inner cells are the source of the stem cells
extracted for research. See id.
26. PANNO, supra note 3, at 77.
27. Id.; see also Susan L. Crockin, The "Embryo" Wars: At the Epicenter of
Science, Law, Religion, and Politics, 39 FAM. L.Q. 599, 601 (2006); Elizabeth A.
Trainor, Annotation, Right of Husband, Wife, or Other Party to Custody of Frozen
Embryo, Pre-embryo, or Pre-zygote, in Event of Divorce, Death, or Other
Circumstances, 87 A.L.R.5th 253, 259 (1991). Although such distinctions are
compelling, for simplicity purposes I will continue to refer to the group of cells
during their first fourteen days as an embryo for the remainder of this Article.
28. HEROLD, supra note 14, at 123 (stating that only thirty to forty percent of
embryos result in pregnancy).
29. PANNO, supra note 3, at 77.
30. Id.
31. HEROLD, supra note 14, at 135-36.
32. Id.
33. PANNO, supra note 3, at 77.
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acquires the features of a specialized cell such as a heart, liver, or
muscle cell. 34
Likewise, if stem cells are extracted from a blastocyst before
the blastocyst attaches to the uterus, the cells immediately begin
multiplying into additional stem cells, forming what scientists call
a cell line. 35 Unlike a typical human cell, an ESC has not yet
differentiated and can thus multiply into any of a wide variety of
cell types, 36 a trait that could prove useful in repairing damaged or
diseased cells. 37 Many believe stem cells hold the cure to some
currently incurable diseases, injuries, and illnesses, 38 which is
precisely why Dr. Thomson's and Dr. Gearhart's accomplishments
created excitement within the scientific community. 39
Although the possibilities may be endless, the technology is
still wrought with complications. For example, patients
undergoing stem cell therapy face many of the same problems
encountered by organ transplant recipients.4° Because the stem
cells typically consist of DNA different from the patient's, the
patient's immune system can reject the foreign substance. 41
Experts believe therapeutic cloning may be the answer to this
problem. 42 Therapeutic cloning involves extracting the nucleus
from a cell and replacing it with a nucleus from one of the patient's
cells. 43  Once this process is completed, the resulting embryo
begins multiplying until it becomes a blastocyst. 44 At this stage,
the stem cells can be extracted in the normal fashion.45
Therapeutic cloning has three major appealing features: 1) it can
create embryonic stem cells that are 100 percent compatible with
the patient's cells; 2) it provides for an unlimited supply of cells;
34. Richard A. Merrill & Bryan J. Rose, FDA Regulation of Human Cloning:
Usurpation or Statesmanship?, 15 HARV. J.L. & TECH. 85, 93 (2001).
35. See VIEGAS, supra note 3, at 24-25.
36. PANNO, supra note 3, at 24.
37. Id. See also HEROLD, supra note 14, at 41 ("The principle behind stem cell
research is that the formula for self-renewal, and for continuous cellular
replenishment, hides within stem cells-the parent cells that generate new cells.").
38. PANNO, supra note 3, at 58.
39. See id. at 34.
40. Id. at 60.
41. Id. at 59.
42. MICHAEL BELLOMO, THE STEM CELL DIVIDE: THE FACTS, THE FICTION, AND
THE FEAR DRIVING THE GREATEST SCIENTIFIC, POLITICAL, AND RELIGIOUS DEBATE
OF OUR TIME 135-36 (2006). This technique was first performed in 2001. Michael
J. Malinowski & Radhika Rao, Legal Limitations on Genetic Research and the
Commercialization of Its Results, 54 AM. J. COMP. L. 45, 50 (2006).
43. BELLOMO, supra note 42, at 135.




and 3) if it is done properly, the cells produced are totally
rejuvenated independent of the age of the donor.46  Further
research and improvement of therapeutic cloning is essential to
ensure stem cell therapies can later be utilized on human subjects
without fear of immune rejection.47
Although ESCR provides hope for many medical ailments,
most research inherently involves destroying embryos. 4s Because
of this, some people prefer scientists pursue adult stem cell
research ("ASCR"). Adult stem cells ("ASCs") exist throughout the
adult body. 49 Treatment using ASCs directly derived from the
patient circumvents the problem of immune rejection. 50  The
further development of ASCR offers promise for a variety of
diseases and disabilities. 51 Unlike ESCR, ASCR is currently in
the human clinical trial stage of development in this country, 52
and thus its benefits may be more quickly realized.
Although ASCR may lead to promising therapies, there are
limits to what it can achieve. ESCR, on the other hand, is more
versatile and has the potential to assist with a larger array of
medical complications. In part, this is because ESCs have greater
plasticity than ASCs. 53 "Plasticity" refers to a cell's ability to
morph into more than one type of cell. 54 Because the plasticity of
an ASC is less than its embryonic counterpart, 55 ASCs can only
evolve into a limited number of cells. 56
Not only is an ESC's plasticity greater than that of an ASC,
but its multiplication rate is also much faster.57 "It is during the
periods of embryonic and fetal development that the rate of
46. Jose Cibelli, Op-Ed., Wake Up America, WALL ST. J., Mar. 1, 2004, at A16.
47. BELLOMO, supra note 42, at 137.
48. See PANNO, supra note 3, at 23. However, scientists have begun creating
methods to extract stem cells without destroying the embryo. Helen Pearson, Early
Embryos Can Yield Stem Cells... and Survive, 442 NATURE, Aug. 24, 2006, at 858.
Even with these techniques, the ethical controversy still remains because some
believe extraction of stem cells will decrease an embryo's chance of implantation.
Id.
49. See PANNO, supra note 3, at 10.
50. BELLOMO, supra note 41, at 145.
51. Id. at 144-45. But see Peter Aldhous, Stem Cells: Miracle Postponed, NEW
SCIENTIST, Mar. 11, 2006, at 39, available at http://genetics-and-society.org/
article.php?id=1842 (suggesting many of the promises made through ASCR were
overstated and unrealistic).
52. BELLOMO, supra note 42, at 144.
53. PANNO, supra note 3, at 1; VIEGAS, supra note 3, at 38-39.
54. PANNO, supra note 3, at 1.
55. Id. at 9.
56. VIEGAS, supra note 3, at 38-39.
57. Id. at 39.
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production of new cells is at its highest."5 8 Additionally, ASCs are
more difficult for scientists to extract and have a more limited life
span when grown in a lab. 59 ASCs will continue to aid important
research in the promise of benefits; however, their promise does
not compare to that provided by ESCR. As one expert notes, ESCs
contain the potential to address every disease to which our species
is susceptible. 60 Even still, ESCR in the United States has been
met with political resistance and skepticism, partly due to pre-
existing legal precedent addressing related, yet distinguishable,
procedures while ignoring more fitting comparisons.
II. Somewhere in Between: Struggling to Categorize Stem
Cell Research Among Policies Regulating Alternative
Reproductive Technologies and Abortion Procedures
Although ESCR may lead to groundbreaking discoveries for
the treatment of many currently incurable diseases and injuries,
many politicians and legal scholars are reluctant to welcome the
technologies with open arms. 61 Destruction of embryos involved in
research troubles some who prefer the development of ASCR to
ESCR.62 This discomfort is improperly linked to the American
divide over abortion rights and should instead be analogized to
other experiments involving human tissues or other procedures
that destroy embryos.
A. Then There Was Roe: The Effect of Fetal
Experimentation Regulations on Research
Although fetal experimentation has existed since the 1930S,63
regulation of these procedures did not become popular until the
mid-1970s, after the Roe v. Wade64 decision legalized abortion. 65
Before Roe, pro-life advocates concentrated their anti-abortion
arguments on the woman's disposition and the importance of
safeguarding family values, focusing only passively on the
58. DANIEL R. MARSHAK ET AL., STEM CELL BIOLOGY 3 (2001).
59. VIEGAS, supra note 3, at 38-39.
60. BELLOMO, supra note 42, at 146.
61. PANNO, supra note 3, at 72.
62. BELLOMO, supra note 42, at 146.
63. NAT'L BIOETHICS ADVISORY COMM'N, supra note 7, at 29.
64. 410 U.S. 113 (1973).
65. Charles H. Baron, Legislative Regulation of Fetal Experimentation: On
Negotiating Compromise in Situations of Ethical Pluralism, in GENETICS AND THE
LAW III 431, 431 (Aubrey Milunsky & George J. Annas eds., 1984); Crockin, supra
note 27, at 603.
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preservation of fetal life.66 Conversely, modern pro-life advocates,
concentrate their abortion protests on the "sanctity of life." 67 This
central focus is perhaps the reason why so many states began
adopting bans on fetal experimentation in the late 1970s and early
1980s.68 By 1984, twenty-five states had enacted some form of
restriction on fetal experimentation, 69  creating a harsh
environment for the research before it ever began. With the
development of ESCR, many of these laws have been interpreted
or amended to restrict ESCR.70
The effect of the pro-life movement on ESCR is tragic,
especially considering the selectivity of prohibition against
embryonic and/or fetal destruction. Opponents analogize ESCR to
the termination of developed fetuses; however, these laws are
rarely applied to alternative reproduction technologies.
Interestingly enough, JVF involves the destruction of embryos at a
similar stage of development as ESCR, yet it enjoys much more
limited restrictions.
B. In the Name of Reproduction: Destroying Embryos
During In Vitro Treatments
Developed in the late 1970s, 71 IVF involves the "union of a
sperm and an egg outside the body in a laboratory setting."7 2 The
embryos created through fertilization are then inserted into the
woman's womb for the purpose of impregnation. 73 Several are
injected simultaneously because the rate of implantation using
this method is very low. 74 Because of this uncertainty, more
66. Janet L. Dolgin, Embryonic Discourse: Abortion, Stem Cells, and Cloning,
31 FLA. ST. U. L. REV. 101, 116-19 (2003).
67. Id. at 128 (discussing the strategic decision to focus on "fetal life" rather
then family values in order to better address opposing claims).
68. Baron, supra note 65, at 432, 443 nn.15-26.
69. Id. at 432.
70. See infra Part IV.
71. See THOMAS SCULLY & CELIA SCULLY, PLAYING GOD: THE NEW WORLD OF
MEDICAL CHOICES 152 (1987) (reporting the birth of Louise Brown, the world's first
test-tube baby, in 1978 in Great Britain). The first IVF baby in the United States
was born in 1981. Victor Cohn, First U.S. Test-Tube Baby Is Born, WASH. POST,
Dec. 29, 1981, at Al.
72. VIEGAS, supra note 3, at 58; see also SCULLY & SCULLY, supra note 71, at
160 (describing the process of implanting multiple embryos at once to assure one
attaches, which can sometimes lead to multiple births).
73. HEROLD, supra note 14, at 32-33.
74. Id. at 33. The process can be very difficult for some women, who are forced
to undergo many rounds of implantation of several embryos. See BONNIE




embryos are typically created than needed. 75  These excess
embryos are handled in one of the following ways: 1) destroyed
outright, 76 2) donated to other infertile couples, 3) donated to
scientific research, or 4) suspended in cryopreservation for future
use or until a more permanent decision can be made. 77
Cryopreservation involves freezing the embryos so that the cells do
not continue to multiply.78
Although IVF consequently involves the destruction of
embryos, energetic pro-life advocates focus little attention on IVF
procedures. 79 Perhaps this is because alternative reproduction
technologies destroy embryos in the pursuit of reproduction.
American legal precedent has maintained a certain level of respect
for individual reproductive rights.8 0 "If the right of privacy means
anything, it is the right of the individual, married or single, to be
free from unwarranted governmental intrusion into matters so
fundamentally affecting a person as the decision whether to bear
or beget a child."1 This unique legal and cultural tradition
facilitated America's general acceptance of and successful
commercialization of IVF.82
Alternative reproduction methods at large, and the IVF
procedure specifically,8 3  enjoy minimal federal government
regulation.84 New techniques often bypass the standard animal-
testing requirements or intimate human subject oversight
typically required of traditional medical procedures. 8 5 Although
75. HEROLD, supra note 14, at 33.
76. PANNO, supra note 3, at 78.
77. See George J. Annas & Sherman Elias, Social Policy Considerations in
Noncoital Reproduction, in GENETICS AND THE LAW III, supra note 65, at 147, 153.
78. See, e.g., HEROLD, supra note 14, at 35 ("[F]rozen embryos l[ie] in a state of
suspended animation....").
79. See supra note 9 and accompanying text. But see HEROLD, supra note 14, at
32 (stating some religious and political leaders spoke out against IVF at its
inception).
80. See, e.g., Eisenstadt v. Baird, 405 U.S. 438, 454 (1972) (holding that
"providing dissimilar treatment for married and unmarried persons who are
similarly situated" in terms of contraceptive distribution violates the Equal
Protection Clause of the U.S. Constitution); Skinner v. Oklahoma, 316 U.S. 535,
536 (1942) (noting that "the right to have offspring" is an individual "right which is
basic to the perpetuation of a race").
81. Eisenstadt, 405 U.S. at 453 (citing Stanley v. Georgia, 394 U.S. 557 (1969)).
82. See Lori P. Knowles, Stem Cell Policy: Where Do We Draw the Lines?, 39
NEW ENG. L. REV. 623, 628-29 (2005); Michael J. Malinowski, A Law-Policy
Proposal to Know Where Babies Come from During the Reproductive Revolution, 9
J. GENDER RACE & JUST. 549, 561-63 (2006).
83. Malinowski, supra note 82, at 553-54.
84. Id. at 551-52.
85. Id. at 553-55.
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the Centers for Disease Control and Prevention technically
oversees clinics' practices, it conducts site visits to fewer than ten
percent of IVF facilities.8 6 In response, voluntary organizations
have developed to assist with institutional coordination.8 7 Also,
many individual IVF clinics require that patients expressly
indicate their intentions concerning excess embryos in signed
agreements to avoid any future disputes among the co-donors and
the clinics.88  Even with agreements, legal disputes may
sometimes arise.
Litigation over these contractual arrangements began during
the late 1980s, shortly after the procedure emerged.8 9 Generally,
these cases involve spousal disputes over the disposition of excess
cells created for IVF. 90 Faced with a technological phenomenon of
first impression, courts often resort to traditional common law
analysis and public policy considerations. Courts draw upon
either traditional contract principles, 91 the doctrine of mutual
consent, 92  public' policy considerations, 93  or constitutional
interpretations. 94 Experts analyzing these cases categorize the
86. Id. at 551-52.
87. Id.
88. Laura S. Langley & Joseph W. Blackston, Sperm, Egg, and a Petri Dish:
Unveiling the Underlying Property Issues Surrounding Cryopreserved Embryos, 27
J. LEGAL MED. 167, 168 (2006).
89. See Trainor, supra note 27, at 262-68; see, e.g., In re Baby M, 109 N.J. 396
(1988) (holding a maternal surrogacy contract unenforceable as contrary to public
policy).
90. See, e.g., A.Z. v. B.Z., 725 N.E.2d 1051 (Mass. 2000) (finding unenforceable a
written and signed agreement between a couple and a fertilization clinic to give
frozen embryos to the wife upon separation of the couple); J.B. v. M.B., 751 A.2d
613 (N.J. Super. Ct. App. Div. 2000), affld as modified, 783 A.2d 707 (N.J. 2001)
(modifying lower court holding to allow husband to continue to store frozen
embryos if he wished to pay for the fees associated, ordering the embryos to be
destroyed otherwise).
91. See, e.g., Kass v. Kass, 696 N.E.2d 174 (N.Y. 1998) (limiting the analysis to
interpretation of contract law); Roman v. Roman, 193 S.W.3d 40, 50 (Tex. Ct. App.
2006) ("[A]llowing the parties voluntarily to decide the disposition of frozen
embryos in advance of cryopreservation, subject to mutual change of mind, jointly
expressed, best serves the existing public policy of this State and the interests of
the parties."); Litowitz v. Litowitz, 48 P.3d 261, 271 (Wash. 2002) (en banc) ("We
base our decision in this case solely upon the contractual rights of the parties under
the preembryo cryopreservation contract [which calls for the thawing out of the
preembryos after five years unless decided otherwise by the parties].").
92. See In re Marriage of Witten III, 672 N.W.2d 768 (Iowa 2003); Carl H.
Coleman, Procreative Liberty and Contemporaneous Choice: An Inalienable Rights
Approach to Frozen Embryo Disputes, 84 MINN. L. REV. 55 (1999).
93. A.Z., 725 N.E.2d at 1057 (refusing to enforce, "an agreement that would
compel one donor to become a parent against his or her will" on public policy
grounds); see, e.g., J.B., 751 A.2d at 619 ("[A] contract to procreate is contrary to
New Jersey public policy and is unenforceable.").
94. See, e.g., Davis v. Davis, 842 S.W.2d 588, 590, 602 (Tenn. 1992) (balancing
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decisions as coming under one of three theories: the property
theory, the human life theory, or the special respect theory. 95
Jurisdictions subscribing to the property theory consider the
cells to be personal property, not human life. 96 They often resort
to traditional contract law principles for determining ownership
over the cells. 97 Some of these courts identify the cells as "pre-
zygotes" 98 or "pre-embryos,"99 indirectly implying the tissue should
not be considered embryos, let alone human life. In contrast, the
human life theory declines to enforce contractual agreements
regarding human cells because those cells constitute life incapable
of giving consent. 100 Advocates of this theory align with the pro-
life individuals who oppose ESCR. 101 Finally, proponents of the
special respect theory do not focus on whether or not the cells rise
to the status of living. 102 They suggest that even if the tissue is
not human life, it nonetheless deserves special respect.10 3 Using
this approach, courts refuse to enforce contracts between
donors;1 04 instead, they engage in a public policy or constitutional
analysis to determine the fate of the cells.1 05 Regardless of the
the rights of the parents in the absence of a contract and engaging in a
constitutional analysis, holding "the state's interest in potential human life is
insufficient to justify an infringement on the gamete-providers' procreational
autonomy"). Although the J.B. court's holding rested on public policy grounds, it
nonetheless stated "enforcement of the alleged contract to create a child would
impair the wife's constitutional right not to procreate, whereas permitting
destruction of the embryos would not effectively impair the husband's reproductive
rights. Therefore . . .[rejecting] the husband's contention that his constitutional
rights would be violated by destruction of the embryos." J.B., 751 A.2d at 619.
95. See STEINBOCK, supra note 74, at 208.
96. See, e.g., Litowitz, 48 P.3d at 271 ("It is not necessary... to engage in a...
discussion whether the preembryos in this case are 'children' [rather this decision
is based] solely upon the contractual rights of the parties ... .
97. Id.
98. See Kass v. Kass, 696 N.E.2d 174, 180 (N.Y. 1998) ("Agreements between
progenitors . . . regarding disposition of their pre-zygotes should generally be
presumed valid and binding .... (emphasis added)).
99. See Litowitz, 48 P.3d at 268 ("[Ilt is appropriate for the courts to determine
disposition of the preembryos under the cryopreservation contract." (emphasis
added)).
100. See STEINBOCK, supra note 74, at 208.
101. See infra text accompanying notes 250-52, 261-62.
102. See STEINBOCK, supra note 74, at 208.
103. Id.
104. In the IVF context, I loosely adopt the term "donors" to depict patients with
a legal claim to the embryos whether the embryos are comprised of the "donor's"
actual genetic material.
105. See, e.g., A.Z. v. B.Z., 725 N.E.2d 1051, 1057-58 (Mass. 2000) ("As a matter
of public policy, we conclude that forced procreation is not an area amenable to
judicial enforcement."); Davis v. Davis, 842 S.W.2d 588, 591 (Tenn. 1992) ("[Wle
conclude that given the relevant principles of constitutional law .. . [and] the
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approach, experts argue that the analysis should focus on the
rights of the donors and recipients over the embryos produced for
IVF procedures.106 Indeed, court opinions mention little
concerning the rights of the individual embryos. 1 0 7
In contrast, most laws directed at ESCR are concerned
primarily with protecting individual embryos as life. Therefore,
the Roe decision had a negative effect on one scientific technique
involving the destruction of potential life (fetal experimentation)
while completely ignoring another (alternative reproduction
technology). 108
III. Left in the Dust: How the U.S. Government is Failing
Our Scientific Community
A. The American Position on Embryonic Stem Cell
Research
Although most states increased their restrictions on fetal
experimentation following Roe v. Wade, the federal government's
Ethics Advisory Board ("EAB") of the Department of Health,
Education, and Welfare, currently the Department of Health and
Human Services ("DHHS"), endorsed experimentation on embryos
in gestation less than fourteen days.10 9 In 1983, the President's
Commission on Bioethics also adopted this position. 110
In 1996, shortly before scientists successfully extracted
human ESCs, Congress attached a Dickey Amendment, banning
all federal funding of research involving the destruction of
embryos, to an appropriations bill.11 In response, general counsel
existing public policy of Tennessee ... , we must weigh the interests of each party
to the dispute .. . in order to resolve that dispute in a fair and responsible
manner.").
106. STEINBOCK, supra note 74, at 209.
107. See A.Z., 725 N.E.2d 1051; J.B. v. M.B., 751 A.2d 613 (N.J. Super. Ct. App.
Div. 2000), aff'd as modified, 783 A.2d 707 (N.J. 2001).
108. The majority of pro-life advocates have not actively advocated increased
restrictions on alternative reproduction technology. In light of this inconsistency, a
few pro-life advocates united against Roe have recently begun re-evaluating their
stance on existing IVF policies. See HEROLD, supra note 14, at 75.
109. SCULLY & SCULLY, supra note 71, at 159.
110. Id.
111. The original rider amendment was attached to the Balanced Budget Down
Payment Act, Pub. L. No. 104-99, § 128, 110 Stat. 26, 34 (1996). In the following
years, Congress continued to attach Dickey Amendments to appropriation bills to
continue the restrictions. Departments of Labor, Health and Human Services, and
Education, and Related Agencies Appropriations Act of 2006, Pub. L. No. 109-149, §
509, 119 Stat. 2833, 2880; Consolidated Appropriations Act of 2005, Pub. L. No.
108-447, § 509, 118 Stat. 2809, 3163-64; Consolidated Appropriations Act of 2004,
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for the DHHS interpreted the Amendments' prohibition on human
embryonic experimentation to not apply to research involving stem
cells, 112 pointing to the Amendments' definition of a human
embryo as "any organism, not protected as a human subject ...
that is derived by fertilization, parthenogenesis, cloning, or any
other means from one or more human gametes or human diploid
cells." 113 The general counsel reasoned that because stem cells are
not "organisms" capable of reproduction, the Amendment was
inapplicable to SCR specifically. 114
After this opinion, the DHHS established new federal
guidelines in 2000 to begin disbursing federal funds for human
embryonic stem cell research the next year. 115 The National
Institutes of Health ("NIH") published guidelines allowing federal
funding for human embryonic research as long as: 1) the cells
used came from fertility clinics; 2) the cells were "in excess of the
clinical need," 3) "a clear separation existed between the decision
to create embryos for fertility treatment and the decision to donate
them for research purposes," 4) the cells were obtained with the
informed consent of the fertility patient, and 5) "no inducements
were offered for the donation of the embryos."11 6 President Bill
Pub. L. No. 108-199, § 510, 118 Stat. 3, 277; Consolidated Appropriations
Resolution of 2003, Pub. L. No. 108-7, § 510, 117 Stat. 11, 344; Department of
Labor, Health and Human Services, and Education, and Related Agencies
Appropriations Act of 2002, Pub. L. No. 107-116, § 510, 115 Stat. 2177, 2219; The
Consolidated Appropriations Act of 2001, Pub. L. No. 106-554, § 510, 114 Stat.
2763, 2763A-71; Consolidated Appropriations Act of 2000, Pub. L. No. 106-113, §
510, 113 Stat. 1501, 1501A-275; Omnibus Consolidated and Emergency
Supplemental Appropriations Act of 1999, Pub. L. No. 105-277, § 511, 112 Stat.
2681, 386; Departments of Labor, Health and Human Services, Education, and
Related Agencies Appropriations Act of 1998, Pub. L. No. 105-78, § 513, 111 Stat.
1467, 1517; The Omnibus Consolidated Appropriations Act of 1997, Pub. L. No.
104-208, § 512, 110 Stat. 3009, 270; see also JUDITH A. JOHNSON & ERIN WILLIAMS,
STEM CELL RESEARCH, CRS REP. FOR CONG: RECEIVED THROUGH THE CRS WEB,
RL31015, 5-6, updated July 18, 2005; Crockin, supra note 27, at 620 ("[B]efore any
funding was actually granted, Congress attached a rider to a . . . DHHS . . .
appropriations bill . . . known as the Dickey Amendment . . . [and] to every
subsequent DHHS appropriations bill to date."); Fowler, supra note 12, at 522
("Congress did not agree with the [NIH] recommendation and enacted a federal law
banning the use of appropriated federal funds for [human embryo research].").
112. JOHNSON & WILLIAMS, supra note 111, at 6; Fowler, supra note 12, at 522-
23.
113. See, e.g., § 509, 119 Stat. at 2880. In 1998, "or human diploid cell" was
added to the definition of all subsequent Dickey Amendments. § 513, 111 Stat. at
1517.
114. JOHNSON & WILLIAMS, supra note 111, at 6.
115. Id. at 7.
116. Samuel B. Casey & Nathan A. Adams, Specially Respecting the Living
Human Embryo by Adhering to Standard Human Subject Experimentation Rules, 2
YALE J. HEALTH POL' L. & ETHICS 111, 113 (2001) (citing the National Institutes of
Law and Inequality
Clinton endorsed this position and advocated for research during a
speech in 2000. "[Wie cannot walk away from the potential to save
lives and to improve lives, to help people literally to get up and
walk, to do all kinds of things we could never have imagined, as
long as we meet rigorous ethical standards.""117
Unfortunately, the DHHS was unable to distribute funds
because President George W. Bush altered the executive position
on SCR upon taking office. 118  On August 9, 2001, while
addressing the nation, the President announced his new
restrictions on the federal funding of ESCR.119 Although not
prohibiting SCR, the new policy limits federal grants to research
involving the sixty stem cell lines already in existence at the time
of the speech.120 Under President Bush's plan, no federal monies
are disbursed for experiments involving the further destruction of
embryos.' 2' This policy also prohibits funding for constructing
facilities or purchasing equipment to be used to conduct
unsanctioned ESCR.122 In addition to funding restrictions,
President Bush's new policy also requires that researchers obtain
informed consent of the patients who originally donated the
embryos in which the stem cell lines were derived. 123
In reaction to the federal government's moratorium on SCR
funding, private endowments were established to support the
experimentation.124 Many universities including Stanford, the
University of Wisconsin-Madison, the University of Minnesota,
and the University of California, San Francisco contributed to the
cause. 125  Harvard has gone one step further in building a
privately funded research center. 126  Yet however generous,
private financiers cannot provide an adequate substitute for
federal grants because the cost of research is simply too great. 127
Health Guidelines for Research Using Human Pluripotent Stem Cells, 65 Fed. Reg.
51,976, 51,980 (Aug. 25, 2000)).
117. BELLOMO, supra note 42, at 92.
118. JOHNSON & WILLIAMS, supra note 111, at 9, 12.
119. President Discuses Stem Cell Research, supra note 10.
120. Id.
121. Id.
122. William Hathaway, Stem Cell Funds Draw Interest of 77 Scientists,
HARTFORD COURANT (Conn.), June 7, 2006, at A4.
123. JOHNSON & WILLIAMS, supra note 111, at 35.
124. Id. at 12.
125. Gareth Cook, Stem Cell Center at Harvard: Researchers Seek to Bypass U.S.
Restrictions, BOSTON GLOBE, Feb. 29, 2004, at Al.
126. Id.
127. See CHRISTOPHER THOMAS SCOTT, STEM CELLS Now: A BRIEF
INTRODUCTION TO THE COMING MEDICAL REVOLUTION 171 (2006).
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In 2005, the Republican-led Congress attempted to
circumvent President Bush's 2001 mandate. 128 Unfortunately, the
President exercised his first veto and preserved existing limits to
federally funded research. 129 The President believed compelling
Americans to "fund the deliberate destruction of human embryos
... would be a grave mistake and would needlessly encourage a
conflict between science and ethics that can only do damage to
both and harm our Nation as a whole." 130 Again in 2007, Congress
tried to offer more expansive funding to ESCR. Although the
House 131 and Senate 132 once again passed legislation, Bush
predictably vetoed the measures. 133 It has been over six years
since President Bush implemented his ESCR policy, and scientists'
problems with the remaining cell lines have continued to
increase. 134
B. The Failing Federal Plan
President Bush proudly proclaims himself to be the first
president to support embryonic stem cell research. 135 As the
128. See Stem Cell Research Enhancement Act of 2005, H.R. 810, 109th Cong.
(as passed by House of Representatives, May 24, 2005).
129. President George W. Bush, Message to the House of Representatives (July
19, 2006), available at http://www.whitehouse.gov/news/releases/2006/07/20060719-
5.html (last visited Oct. 28, 2007) [hereinafter Message to the House]; see Editorial,
Bush Readies First Veto, Dashing Hopes of Millions, USA TODAY, July 19, 2006, at
A10.
130. Message to the House, supra note 129.
131. The Stem Cell Research Enhancement Act of 2007 was passed by the House
of Representatives on January 11, 2007. H.R. 3, 110th Cong. (2007).
132. The three Senate bills, The Stem Cell Research Enhancement Act of 2007,
S. 5, 110th Cong. (as passed by Senate, Apr. 11, 2007), The Stem Cell Research
Expansion Act, S. 362, 110th Cong. (2007), and The Hope Offered Through
Principled Ethically-Sound Stem Cell Research (H.O.P.E.) Act, S. 363, 110th Cong.
(2007), were all introduced in January of 2007. The H.O.P.E. Act promoted ASCR,
encouraged the adoption of embryos, and funded research that searched for a
method for obtaining ESCs without destroying embryos. S. 363, §§ 4-5. The Stem
Cell Research Expansion Act mirrored President Bush's policy, but extended the
federal funding deadline for stem cell lines produced before 2001 to all lines
produced before January 23, 2006. S. 362, § 2. The Stem Cell Research
Enhancement Act of 2007, the bill eventually passed by the Senate, provided
federal support for ESCR using in vitro embryos, called for the NIH to establish
research guidelines, and promoted alternative experimentation using non-
embryonic stem cells. S. 5, § 2-3.
133. See Sheryl Gay Stolberg, Bush Vetoes Measure on Stem Cell Research, N.Y.
TIMES, June 21, 2007, at A21.
134. See Fowler, supra note 12, at 528 (discussing the extensive difficulties of
both privately and publicly funded stem cell research in the United States since
President Bush implemented his policies).
135. See, e.g., Message to the House, supra note 129 ("When I took office, there
was no Federal funding for human embryonic stem cell research.").
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White House Administration claims: "people are trying to
politicize . . . [the issue] by accusing him of standing in the way of
science, when he's the guy who's made it possible to open up the
way to science.'' 36 Although President Bush may technically have
been the first to actually distribute federal funds for SCR, it was
President Clinton who laid the framework to support this new
science. 137
President Bush's piecemeal approach to "supporting" SCR is
both under- and over-inclusive, welcoming hostility from
supporters and defenders of the technology alike. First, the policy
only restricts federal funding of research and says little about the
scientific procedures themselves. 138 This policy leaves the field
virtually unregulated by the government so long as experiments
are conducted using private monies. 139  Secondly, the policy
provides funding only for research on stem cell lines available
before the 2001 policy was implemented. 140
Anti-research 41  advocates complain that allowing
experimentation on any embryos improperly validates the
science. 142 Research advocates, on the other hand, consider the
2001 distinction arbitrary, especially since embryos have
continued to be habitually destroyed at IVF clinics long after the
President's speech. 143 "[T]here is no cogent ethical reason for
stopping where his policy stops .... [TIhat temporal restriction is
difficult to defend from an ethical standpoint."144 Meaningless
136. Press Release by Tony Snow, Press Sec'y for the White House, White House
Communications Press Briefing (July 19, 2006), available at
http:www.whitehouse.gov/news/releases/2006/07/20060719-2.html.
137. BELLOMO, supra note 42, at 93 & n.3.
138. See The Stem Cell Research Expansion Act, S. 362, 110th Cong. (2007), and
The Hope Offered Through Principled Ethically-Sound Stem Cell Research
(H.O.P.E.) Act, S. 363, 110th Cong. (2007); Stolberg, supra note 133 (discussing
President Bush's veto of a measure lifting restrictions on stem cell research, while
simultaneously encouraging scientists to pursue "unethical" stem cell research).
139. See SCOTT, supra note 127, at 169-71 (discussing privately-funded medical
advances and the limitations on private research institutions).
140. The H.O.P.E. Act would have extended this deadline to January 23, 2006.
See supra note 132 and accompanying text.
141. "Pro-life" may be a more neutral term to describe these advocates; however,
many pro-life, meaning anti-abortion, advocates support ESCR; therefore the term
"pro-life" is not necessarily synonymous with "anti-research."
142. See JOHNSON & WILLIAMS, supra note 111, at 34 ('The National Right to
Life Committee and the United States Conference of Catholic Bishops, object [to
the distinction] because the distinction validates the destruction of embryos.").
143. HEROLD, supra note 14, at 36-37.
144. James F. Childress, An Ethical Defense of Federal Funding for Human




destruction of cells may be prohibited by some state laws, 145 but
the alternative fate of indefinite cryopreservation may be
compared to a slow death sentence. 146 The longer embryos remain
frozen, the harder they are to thaw, insert into a surrogate uterus,
and develop to term. 147
The problems with President Bush's ESCR policy are not
limited to its under- and over-inclusive nature. Further issues
arise due to the very limited quantity of research permitted using
federal funds. During his 2001 speech, the President suggested
sixty stem cell lines were available for research; 148 however,
scientists estimate the actual number of lines available for
research in the United States to be twenty-two or twenty-three. 149
Furthermore, the number of available lines appears insignificant
when one considers that, as of 2003, an estimated 400,000 frozen
excess embryos existed in the United States. 150
Scientists worry that the existing twenty-some stem cell lines
listed on the NIH registry may be contaminated because of the
mouse "feeder" cells used on the cell lines. Mouse "feeder" cells
keep cell lines from differentiating by excreting chemicals,' 5 '
which scientists suspect leave stem cells vulnerable to potential
145. See, e.g., LA. REV. STAT. ANN. § 9:129 (2006); infra Part TV.
146. Of course, this "death sentence" analogy only makes sense if one assumes a
presence of life.
147. See HEROLD, supra note 14, at 35-36 (discussing the dilemma of what to do
with the 400,000 frozen embryos, half of which may not survive the thawing
process).
148. President Discusses Stem Cell Research, supra note 10, at 142. In fact, the
Human Embryonic Stem Cell Registry, developed by the NIH after the new policy
was implemented, actually estimated the number of lines available throughout the
world to be closer to seventy-eight. JOHNSON & WILLIAMS, supra note 111, at 2, 10-
11.
149. See HEROLD, supra note 14, at 64; JOHNSON & WILLIAMS, supra note 111, at
11-12; Editorial, supra note 129, at A10, Marta Brodsky, The Viability of Our
Humanity: Will the Supreme Court's Abortion Jurisprudence Survive the Challenge
of Embryonic Stem Cell Research?, 76 ST. JOHN'S L. REV. 225, 247 (2002)
(discussing U.S. scientists' frustration with the limited number of stem cell lines
available under President Bush's federal funding restriction). Of the seventy-eight
lines world-wide reported by the NIH, thirty-one are not kept in the United States,
sixteen perished while being thawed out of cryopreservation, seven were in fact
duplications of lines already accounted for, one line was still in development at the
time of the speech, and one was withdrawn from the original count. SCOTT, supra
note 127, at 164-65.
150. HEROLD, supra note 14, at 35 (reporting that 400,000 embryos exist in a
state of suspended animation, and scientists estimate that only about half that
number will survive the process of thawing out of cryopreservation); Crockin, supra
note 27, at 609.
151. HEROLD, supra note 14, at 64; JOHNSON & WILLIAMS, supra note 111, at 9
("The mouse cells secrete a substance that prevents the human embryonic stem
cells from differentiating into more mature cell types .... ").
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viral infections. 152 These viruses can remain undetected for many
years.' 53  Since scientists discovered this potential problem,
researchers in Singapore created a technique to preserve stem cell
lines without the use of mouse "feeder" cells. 54 Unfortunately, the
damage has already been done to the cell lines eligible for federal
funds in this country.
IV. Choosing Sides: A Shift in State Research Policies
In addition to the national restrictions prohibiting federal
funding for ESCR, some states chose to impose even more
stringent limitations on experiments conducted within their
borders. The most sweeping of these laws belongs to Louisiana.
In congruence with the human life theory, Louisiana's statute
defines an embryo as a "juridical person" deserving of human
rights until it is implanted in a woman's womb or until it fails to
develop outside of cryopreservation within a thirty-six hour time
frame. 155 In considering the embryo a legal person, Louisiana
does not acknowledge property claims of ownership over the
tissue' 5 6 and expressly prohibits the sale 157 or intentional
destruction15 8 of the cells, thus restricting the use of cells to
alternative reproduction purposes only. "The use of a human
ovum fertilized in vitro is solely for the support and contribution of
the complete development of human in utero implantation."'159
Unwanted frozen embryos are only available for adoption by other
couples. 160
Although the Louisiana statute is the most restrictive, other
states have adopted similar provisions. Many states statutes
expressly prohibit experimentation on embryos and/or fetuses' 6'
152. See HEROLD, supra note 14, at 64 (noting that the mouse feeder cells caused
the stem cells to be subjected to possible rodent disease).
153. JOHNSON & WILLIAMS, supra note 111, at 9.
154. HEROLD, supra note 14, at 64.
155. LA. REV. STAT. ANN. §§ 9:123, :129 (2006).
156. LA. REV. STAT. ANN. § 9:126 ("An in vitro fertilized human ovum is a
biological human being which is not the property of the physician.., or the facility
.... "); LA. REV. STAT. ANN. § 9:130 ("An in vitro fertilized human ovum is a
juridical person which cannot be owned ....
157. LA. REV. STAT. ANN. § 9:122.




161. See, e.g., ARIZ. REV. STAT. ANN. § 36-2302 (2006); FLA. STAT. § 390.0111(6)
(2006); MASS. ANN. LAWS ch. 112, § 12J(a)(I) (LexisNexis 2006); MICH. COMP. LAWS
ANN. §§ 333.2685, .2688 (West 2006); MINN. STAT. § 145.422, subd. 1 (2006); N.D.
CENT. CODE § 14-02.2-01 to -02 (2006); 18 PA. CONS. STAT. ANN. § 3216(a) (West
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and forbid the sale or donation of embryos and/or fetal tissue.162
As of 2002, thirty-seven states recognized some level of "life"
attributed to human embryos. 163
With the majority of states limiting research funds or
restricting experimentation altogether, a minority of progressive
state governments have begun contemplating safe, responsible
ways to permit SCR and experimentation.164 Those states that are
considering SCR-friendly policies not only wish to provide relief to
their suffering citizens, but they also hope to become leaders in an
innovative scientific industry. Some states worry about a "brain
drain" effect, whereby prominent scientists from leading
institutions migrate to other states and counties to conduct
research. 165 Massachusetts recently loosened its restrictions on
ESCR,166 and Missourians voted in 2006 to legalize ESCR and
therapeutic cloning.167 Removing state-mandated research
barriers is certainly a fresh start to promoting the technology, but
more proactive measures are necessary.
New Jersey recently considered allocating $200 million to the
construction of three research facilities. 16  Illinois followed suit by
providing ten million dollars of state funding to support SCR, 169
which will be used to establish new research facilities. Likewise,
2006); S.D. CODIFIED LAWS § 34-14-16 to -18 (2006). Notably, some statutes limit
experimentation to aborted fetuses with the consent of the mother as long as the
fetus was not aborted for research purposes. See ARK. CODE. ANN. § 20-17-802
(2006); R.I. GEN. LAWS § 11-54-1(d) (2006).
162. See, e.g., ARK. CODE. ANN. § 20-17-802(c) (2006); KY. REV. STAT. ANN. §
436.026 (LexisNexis 2006) (restricting the sale of viable aborted child); MASS. ANN.
LAWS ch. 112, § 12J(a)(lV) (LexisNexis 2006); MICH. COMP. LAWS ANN. § 333.2690
(West 2006); MINN. STAT. § 145.422, subd. 3 (2006); R.I. GEN. LAWS § 11-54-1(f)
(2006).
163. Casey & Adams, supra note 116, at 124 n.154.
164. E.g., HEROLD, supra note 14, at 152; Editorial, The States Confront Stem
Cells, N.Y. TIMES, Mar. 31, 2006, at A18(L) [hereinafter The States Confront Stem
Cells].
165. E.g., HEROLD, supra note 14, at 145-49.
166. Massachusetts Allows Work on Embryo Stem Cells, STAR-LEDGER (N.J.),
June 1, 2005, at 8.
167. MO. CONST. art. III, § 38(d) (2006).
168. BELLOMO, supra note 42, at 79.
169. See BELLOMO, supra note 42, at 80; John Chase, Governor Slips Stem-Cell
Grant by Lawmakers: Illinois Joins States Opposing Bush Stand, CHI. TRIB., July
13, 2005, at 1. Illinois once restricted stem cell research. After the state
legislature attempted in vain to loosen these restrictions, the Governor issued an
executive order providing state support. See Ill. Exec. Order No. 6 (July 12, 2005).
The Order became law when it was snuck into a single line of an appropriations bill
under the general guise of "scientific research" making no reference to stem cells
specifically. Chase, supra note 169.
20081
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Wisconsin has plans to construct similar institutions. 170 Although
beneficial, these states' measures are currently limited to funding
the construction of facilities and do not provide monies directly for
embryonic research itself.
Alternatively, some state officials propose the allocation of
money directly to embryonic experimentation. In 2007, Maryland
began disbursing fifteen million dollars in state funding, 171 and
New York's Governor hopes to disburse two billion dollars over ten
years. 172 Although these states are slowly beginning to draft
research funding policies, they have not yet provided
comprehensive research strategies to both disburse funds and to
regulate experimentation.
Adopted in 2002, California's Proposal 71 does just that. The
proposal declares SCR a state constitutional right, expressly
prohibits human reproductive cloning, and allocates three billion
dollars over a ten year period to SCR.173 The funding scheme
specifically gives priority to ESCR.174 Although the law provides a
copious funding gift, a detailed distribution framework, and
regulatory procedures, the benefits of Proposal 71 are only now
becoming realized. Proposal 71 was tied up in lawsuits
challenging its legal validity until early 2007.175 Opponents
brought suit challenging its funding methodology and its validity
under state voting procedure. 176 In February 2007, the California
Court of Appeals upheld the law, 177 and the California Supreme
Court refused to take the case on appeal in May 2007.178 As a
result of this litigation, California just began distributing the
three billion dollars earlier this year. 179  Similarly, most states
that provide research assistance are just beginning their
170. Chase, supra note 169.
171. Associated Press, Maryland: Stem Cell Grants, N.Y. TIMES, May 19, 2007,
at A10; Robert J. Terry, Stem Cell Commission Extends Funding Application
Deadline, BALTIMORE Bus. J. (Md.), Dec. 13, 2006, available at
http://www.bizjournals.com/baltimore/stories/2006/12/111/daily22.html (last visited
Oct. 28, 2007).
172. Nicholas Confessore, Spitzer Wants New York to Enter the Stem Cell Race,
N.Y. TIMES, Jan. 16, 2007, at B1-2.
173. BELLOMO, supra note 42, at 66-69.
174. Id. at 66.
175. Andrew Pollack, California Stem Cell Research is Upheld by Appeals Court,
N.Y. TIMES, Feb. 27, 2007, at All.
176. Id.
177. Id.
178. Mary Engel, Hurdle to Stem Cell Funds Cleared, L.A. TIMES, May 17, 2007,
at B1.
179. Pollack, supra note 175.
[Vol. 26:133
PRESSING FORWARD
programs. 18 0 However, Connecticut has already implemented its
comprehensive research regulations and begun distributing state
funds directly to research. 181
V. One State Steps Up: Connecticut's Expansive Approach
In June 2005, Connecticut enacted a stem cell research policy
both allocating one hundred million dollars of state funds over a
ten year period to SCR and creating state regulations of privately
and publicly funded experimentation. 8 2 This statute serves as a
model to other states because it is generous to all types of SCR183
while simultaneously providing clearly defined ethical
boundaries.'8 4 Such an approach not only strengthens a state's
economy and academic prestige, 8 5 it also strengthens the hope
held by millions of Americans today who suffer from debilitating
diseases or injuries. Until this country is willing to adopt a more
science-friendly approach to embryonic stem cell research, states
concerned with the quality of life of their citizens will be forced to
make up for the lack of national support. Connecticut's statute
has gained international attention thus far,18 6 and should be
viewed as a model to other states hoping to facilitate the
advancement of this exciting science. 8 7
A. Increased Regulation of Permitted Technologies
Although some states impose blanket prohibitions on
research, SCR remains largely unregulated in this country, much
like the IVF industry.1 88  Connecticut provides carefully
180. See, e.g., supra text accompanying notes 171-72.
181. Infra Part V and accompanying text.
182. CONN. GEN. STAT. §§ 19a-32d to -32g (Supp. 2007).
183. Infra Part V.B.
184. Infra Part V.A.
185. E.g., HEROLD, supra note 14, at 145-49.
186. See, e.g., Press Release, Conn. Dep't of Pub. Health, United Kingdom
Parliament Members Visit Connecticut to Learn About State's Stem Cell Research
Efforts, (Sept. 19, 2006) (on file with author), available at http://www.ct.gov/dphl
cwp/view.asp?a=3115&q=387232&dphNav_GID=1835 (follow "United Kingdom
Parliament Members Visit Connecticut to Learn About State's Stem Cell Research
Efforts" hyperlink) (demonstrating British interest in the Connecticut statute).
187. See Jennifer Medina, Connecticut Takes a Lead in Stem-Cell Research Aid,
N.Y. TIMES, Dec. 10, 2006, at A47(L) ("Connecticut is moving faster and further
than other states .... ).
188. See Childress, supra note 144, at 162-63; Malinowski & Rao, supra note 42,
at 56 (proposing increased government regulations of alternative reproduction
procedures). Close regulation of both technologies is more commonplace in
countries that allow research. See PANNO, supra note 3, at 77; Childress, supra
note 144, at 162; Knowles, supra note 82, at 625-27.
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constructed regulatory provisions that establish enumerated
guidelines and review committees to responsibly disperse funds
and actively regulate research no matter how projects are
funded. 189 Along with the federal research policy, Connecticut also
provides carefully mandated procedures for obtaining donors'
consent to perform research on embryos obtained from IVF
clinics; 190 however, unlike the federal government, Connecticut
funds experimentation on properly obtained embryos created after
2001.191 At the same time, the statute encourages diverse stem
cell experimentation by distributing funds to both ESCR and
ASCR,192 creating a healthy balance of assistance and regulation
of this newly emerging field.
1. A Watchful Eye: The Establishment of Review
Committees
The Connecticut Statute establishes a two-committee system
to ensure research within the state's borders complies with
generally accepted scientific codes of conduct and also that state
money is properly utilized by deserving scientists and
institutions. 193 The two committees function together as a team
providing a check on one another. Additionally, their diverse
membership 194 guarantees the consideration of a variety of
viewpoints.
a. The Diversity of Perspective
The Stem Cell Research Peer Review Committee ("Peer
Review Committee") consists of five members appointed by the
State Commissioner of Public Health. 195 Members cannot serve
for more than two consecutive terms of four years. 196 The state
law also prohibits any one member from serving consecutively on
the Advisory Committee and the Peer Review Committee. 197
The Stem Cell Research Advisory Committee ("Advisory
Committee") is led by the State Commissioner of Public Health,
acting as chairperson, and includes eight other members
189. CONN. GEN. STAT. §§ 19a-32e, -32f (Supp. 2007).
190. CONN. GEN. STAT. § 19a-32d(c)(3) (Supp. 2007).
191. § 19a-32e(c).
192. See § 19a-32e(c).
193. CONN. GEN. STAT. §§ 19a-32f to -32g (Supp. 2007).
194. §§ 19a-32f(a), -32g(a).
195. § 19a-32g(a).
196. Id.
197. §§ 19a-32f(a), -32g(a).
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appointed by various government officials.1 98 The Governor elects
two members, while the Speaker of the State House of
Representatives, the President of the State Senate, and the
majority and minority leaders of both Houses all elect one member
each. 199 Similar to the Peer Review Committee, the Advisory
Committee members cannot serve more than two four-year
terms. 200
Each government official must elect an Advisory Committee
member based upon statutorily expressed qualifications, ensuring
a well-rounded board with diverse experience and expertise.
2 °1
Each of the Governor's two candidates must be "nationally
recognized as an active investigator in the field of stem cell
research and [have] experience in the field of bioethics," while the
Senate President and Speaker's selections must have "experience
in private sector stem cell research and development." 20 2 Both
congressional majority leaders' selections provide the scholarly
perspective of "academic researchers specializing in stem cell
research." 20 3 The Senate Minority Leader has broad discretion to
appoint a member with research and development experience in
either the public or private sector in a wide variety of scientific
fields.20 4 The House Minority Leader balances this voice with a
member who has expertise in "business or financial investments,"
although there is no express requirement that his or her
investment background relate to SCR or any other scientific
topic. 205
b. Research Receiving Connecticut Monies: Who
Can Do What
These diverse committee-bodies work together to ensure the
appropriate use of government monies. 206 They draft guidelines
and applications for distributing funds, and they evaluate the
ethical implications of each proposal. 20 7 This two-step process
provides a check on each committee's findings, and preserves the








206. The Stem Cell Research Fund is essentially a collection of public and
private donations set aside for ESCR. CONN. GEN. STAT. § 19a-32e(a) (Supp. 2007).
207. CONN. GEN. STAT. §§ 19a-32f, -32g (Supp. 2007).
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integrity of the process against anti-research attacks.
The statute requires that the Peer Review Committee consult
the National Academies Guidelines for Human Embryonic Stem
Cell Research when evaluating research proposals. 20° This helps
the Connecticut standards to coincide with national scientific
community standards. Relying on scientific codes of ethics allows
Connecticut to defer to informed professionals rather than agenda-
driven politicians. 209 After consulting uniform ethical guidelines,
the Peer Review Committee, made up of professionals, must draft
its own guidelines in compliance with the statute and make
recommendations to the Advisory Committee in accordance with
these considerations. 210
The Advisory Committee then makes the ultimate decision of
how to allocate the funds. 211 In order to achieve this goal, the
Advisory Committee is entrusted with the following objectives:
(1) [to] develop.., a donated funds program to encourage the
development of funds other than state appropriations...
(2) [to] examine and identify specific ways to improve and
promote for-profit and not-for-profit embryonic and human
adult stem cell and related research in the state, including,
but not limited to, identifying both public and private funding
sources for such research, maintaining existing embryonic and
human adult stem-cell-related businesses, recruiting new
embryonic and human adult stem-cell-related businesses to
the state and recruiting scientists and researchers in such
field to the state,
(3) [to] establish and administer.., a stem cell research grant
program which shall provide grants-in-aid to eligible
institutions for the advancement of embryonic or human adult
stem cell research ... and
(4) [to] monitor the stem cell research conducted by eligible
institutions that receive such grants-in-aid. 212
The Advisory Committee was charged with developing an
application by June 30, 2006 and was to begin accepting
applications and distributing funds after that date. 213  At a
minimum, the statute's application requires the following: a
description of the grant-seeking organization, a proposal for use of
208. § 19a-32g(e).
209. Massachusetts's policy takes a similar approach. Massachusetts Allows
Work on Embryo Stem Cells, supra note 166, at 8 (referring to Massachusetts's new
law expanding research and allowing the state health department regulatory
control).
210. § 19a-32g(c) to (e).
211. § 19a-32f(e).
212. Id.
213. CONN. GEN. STAT. § 19a-32e(b) (Supp. 2007).
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the research money, and a statement regarding the future state
profit sharing plans should the discoveries become financially
beneficial. 214
Unfortunately, the disbursement of grants was delayed by
the Office of State Ethics due to possible conflicts of interest.215
Many committee members have professional connections with two
of the primary institutions applying for grant money. 216 These
potential conflicts concerned the Office. It worried the funds
would be disproportionately distributed among all deserving
applicants, and that the proposed research would not be
adequately scrutinized if committee members had direct interests
in approving certain grants. 217
The ESCR scientific community is a small one, and this
problem is difficult to avoid. Fortunately, some safeguards are in
place to minimize potential conflicts. Not all members of the
committees are from Connecticut. 2 18 Also, more scientists will be
made available to serve on the boards as the ESC scientific
community, both inside and outside of the state, continues to grow.
Even if many of the scientists come from a select few institutions,
geographic diversity and competing interests still exist among
those scientists. The qualification requirements laid out in the
statute only further assure a diverse professional perspective is
available for making important ethical and funding choices.
Further, committee decisions are always evaluated by the State
Commissioner of Public Health, who also chairs the Advisory
Committee. 219
Shortly after this ethics delay, the Advisory Committee began
accepting grant requests. In the summer of 2006, the committee
received over seventy applications requesting more than sixty
million dollars in state grants, 220 quite a bit more than the twenty
million dollars allocated to the first year of the program. The
214. § 19a-32g(e).
215. William Hathaway, Ethics Quandary Holds up State Stem Cell Money,
HARTFORD COURANT (Conn.), Apr. 19, 2006, at B1.
216. Most committee members have ties to Yale University or the University of
Connecticut. Id.; William Hathaway, Stem Cell Grants Now Available, HARTFORD
COURANT (Conn.), May 10, 2006, at B9.
217. Hathaway, supra note 215, at B1.
218. Office of Research and Dev., Conn. Dep't of Pub. Health, Connecticut Stem
Cell Research Program Committees, http://www.ct.gov/dph/site/default.asp (follow
"Programs and Services" hyperlink; then follow "Stem Cell Research" hyperlink;
then follow "SCR Committees" hyperlink) (last updated Oct. 17, 2007).
219. CONN. GEN. STAT. § 19a-32g (Supp. 2007).
220. William Hathaway, Race Is on for Stem Cell Dollars, HARTFORD COURANT
(Conn.), July 19, 2006, at Bi; Hathaway, supra note 122, at A4.
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awards were announced on November 21, 2006.221 Over half of
the twenty million dollars went to projects at the University of
Connecticut, and the other half was divided among Yale and
Wesleyan universities. 222  Despite the many new facility
construction requests, 223 all of the money earmarked for 2006 was
distributed to research projects. 224 'The grants will be used to
equip labs, train researchers and to study how embryonic cells
change to specialized cells ... ,"225 Some of these exciting research
projects include studies on the treatment of war wounds, epileptic
seizures, Parkinson's Disease, degenerative brain disease, mental
retardation, Leukemia, and cancer.226 The hope is these studies
will progress science further towards finding cures for many of the
ailments SCR seeks to eradicate.
However generous Connecticut's $100 million of funding may
be, it will quickly be absorbed by this expensive and under-funded
field. SCR is incredibly expensive for any one state to support. In
assessing Illinois's ability to "make a significant impact" on the
industry, Professor Janet Rowley estimated $500 million to $1
billion in funding would be needed over ten years. 227 President
Bush's policy has done little to relieve the cost burdens states are
forced to absorb in order to remain globally competitive. The NIH
distributed $28.6 billion in 2005 for research programs, but of that
amount, only $27 million were disbursed in support of ESCR.228 It
will take more than $100 million from a single state for American
scientists to realize the goal of effectively treating people with
diseases and disabilities.
221. Press Release, Conn. Dep't of Pub. Health, State of Connecticut Allocates
$19.78 Million in Stem Cell Research Funds (Nov. 21, 2006) (on file with author),
available at http://www.ct.gov/dph/cwp/view.asp?a=3115&q=387232&dphNav_
GID=1835 (follow "State of Connecticut Allocates $19.78 Million in Stem Cell
Research Funds" hyperlink).
222. Id.
223. Hathaway, supra note 122, at A4 (citing Yale University's and the
University of Connecticut's applications requesting more than twelve and one half
million dollars to support the construction of three new research institutions).
224. Conn. Dep't of Pub. Health, supra note 221.
225. Editorial, Connecticut a Leader in Stem Cell Research: Despite Later Start,
Connecticut's Grants Exceed California's Effort, NEW HAVEN REGISTER (Conn.),
Nov. 29, 2006.
226. Medina, supra note 187, at A47(L); Conn. Dep't of Pub. Health, supra note
221. The funds are being used to support both ESCR and ASCR alike. Hathaway,
supra note 220, at B1.
227. Chase, supra note 169, at 1.
228. SCOTT, supra note 127, at 171.
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2. Expressed Regulation of Both Privately and
Federally Funded Research
Along with creating review committees to disburse funds and
regulate research, Connecticut's statute also provides a few
explicit guidelines and restrictions. The state permits SCR within
its borders as long as the conductor complies with the following
requirements:
(1) the research is conducted with full consideration for the
ethical and medical implications of such research,
(2) the research is conducted before gastrulation occurs,
(3) prior to conducting such research, the person provides to
the Commissioner of Public Health documentation verifying
that any human embryos, embryonic stem cells, unfertilized
human eggs or human sperm used in such research have been
donated voluntarily...
(4) the general research program under which such research is
conducted is reviewed and approved by an institutional review
committee, as required under federal law, and
(5) the specific protocol used to derive stem cells from an
embryo is reviewed and approved by an institutional review
committee. 229
Even though Connecticut did not establish a licensing system to
control privately funded research, the aforementioned regulations
apply to scientists regardless of their funding source. 230
Preserving ethical boundaries for both private and public
research serves the additional purpose of promoting public
confidence in experimentation. Many opponents of ESCR worry
about the negative effects of research gone wild. "Such limitations
are a means of addressing concerns about inappropriate uses of
embryos in research." 231  Two possible negative byproducts
concerning many anti-researchers are the potential for human
reproductive cloning and the establishment of a black market
where women are compensated for providing eggs, embryos, and/or
aborted fetuses to research. 232  The statute addresses these
concerns by prohibiting scientists from partaking in research
involving reproductive cloning 233 and by forbidding donors from
229. CONN. GEN. STAT. § 19a-32d(d) (Supp. 2007).
230. Id.
231. See Knowles, supra note 82, at 629 ("Support for oversight of embryo
research is in part a desire to ensure that objectionable scientific research is not
being conducted out of sight.").
232. See Childress, supra note 144, at 163 (urging closer regulation of research





receiving compensation for their tissue.234 Violators of both of
these statutory provisions are subject to possible fines and
imprisonment.235 These enumerated guidelines, along with those
established by the Peer Review Committee, help establish finite
boundaries well beyond the few implemented by the federal
government. As the technology advances, government supervision
becomes more and more necessary to assure individual scientists
are not crossing the ethical line drawn by professionals.
3. The Property-Theory Approach: Donors' Consent
The Connecticut approach also regulates the extraction of
stem cells from embryos provided by IVF patients. It requires
donors of embryos and other fetal tissue to exercise "informed and
voluntary" written consent in making their decisions. 236 To better
inform the donor's choice, the state requires that the donor receive
"timely, relevant and appropriate information," including
notification of alternative disposal methods for unused embryos. 237
In requiring donors' consent for scientific use of IVF clinic
embryos, Connecticut adheres to the property theory. This
approach finds support in some of the existing case law addressing
legal control over frozen embryos from IVF clinics. 238 In reality,
many embryos produced for IVF go unused. Requiring donors to
make informed contractual decisions regarding their leftover
tissue before beginning this highly emotional process is ideal. 239
Many IVF clinics are already well-equipped with carefully drafted
consent forms. 240 Very little would need to be altered to comply
with Connecticut's new regulations. 241
Some opponents of this contractual method claim the
approach ignores the complicated and often emotional process of
IVF. "[R]equiring couples to make binding decisions about the
future use of their frozen embryos ignores the difficulty of
predicting one's future response to life-altering events such as
parenthood." 24 2 This difficulty, however, only strengthens the
234. § 19a-32d(c)(3).
235. § 19a-32d(b), (c)(4).
236. § 19a-32d(c)(1).
237. § 19a-32d(c)(1) to (2).
238. Supra note 91 and accompanying text.
239. Langley & Blackston, supra note 88, at 201-03.
240. See id. at 168.
241. Clinics could likely comply by adding clauses offering the option to donate
cells to science, and by implementing procedures for providing information to assist
patients with the decision-making process.
242. Coleman, supra note 92, at 89.
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need for a mutual and definitive agreement. "[Ilt is illogical to
argue that parties faced with a business-like transaction, though
admittedly intensely personal in nature, would be more emotional
than parties in the middle of a divorce or parties faced with the
death of a significant other. 243  These decisions should be well
informed and contemplated for the good of all involved. To
conduct business, IVF clinics need to maintain a finite expectation
that, once an embryo is frozen, its disposition has been
predetermined. 244 "Defining embryos as property generally is the
only practical route."245
Property disputes over frozen embryos have existed since the
late 1980s 24 6 and will continue to arise as long as IVF persists.
Donating ESCs to science should not alter this significantly.
Intuitively, a donor could more easily change her mind regarding
her decision to allow another person to carry her genes to term
than her decision to donate the cells to research. Donor couples'
relationships change over time and with that so does their intent
to bear future children together. Conversely, a donor's informed
position on the morality of SCR may be less likely to flail so easily.
If a donor is able to make an informed decision in favor of research
in the present, what are the chances he will want to retract such a
decision later? In the future, if the donor wishes to bear more
children, then more embryos may again be produced.
Alternatively, if a donor is unsure of her stance regarding ESCR in
the present, then she may cautiously elect not to donate the
embryos.
Connecticut's informed consent approach allows each
individual donor and future recipient of ESC therapies to
determine his or her own moral position on the issue. 247
It matters not that most would not hesitate to accept organ
donation from the victim of a carjacking and murder; while
they might mourn the necessity of finding their own lives
saved through the death of another, in no way would they feel
that their acceptance of this gift of life made them complicit in
the underlying brutality of the victim's death. 248
In fact, Connecticut's policy requiring donors' consent is consistent
243. Langley & Blackston, supra note 88, at 205.
244. Id.
245. Id. at 203.
246. Supra notes 89-108 and accompanying text.
247. President Bush's ESCR policy also requires the consent of the donors of the
available stem cell lines. JOHNSON & WILLIAMS, supra note 111, at 27.




with many existing ethical rules governing experimentation on
human subjects. 249
Human life theory proponents contend that this consent 250
requirement does not properly take into account the embryos' best
interests because the consent is derived from the "parent" and not
the embryo itself.251 "[W]e should be seriously concerned about
authorizing medical research certain to kill incompetent living
human subjects . ... "252 Potential life, however, is not
synonymous with incompetent life. Equating embryos with
incapacitated or incompetent persons is disingenuous. It is
particularly interesting that anti-research advocates express such
concern for incompetent persons while offering minimal
compassion for those already born individuals who suffer from
debilitating diseases or disabilities and hope to one day benefit
from ESCR and its future therapies.
Anti-research advocates who cite the human life theory align
well with other right-to-life supporters. 253 In fact, some believe
that an anti-research victory over the ESCR issue is a crucial step
towards overturning abortion rights. 25 4 One pro-life organization
has already brought a class action law suit on behalf of a fictitious
embryo in California claiming the state's research policy violates
the federal and state constitutional rights of the frozen embryo. 255
Presently, courts avoid ruling on the merits of such claims, though
they will have to directly address these arguments sooner or later.
249. See JOHNSON & WILLIAMS, supra note 111, at 27. But see Casey & Adams,
supra note 116, at 118 (questioning whether "even a competent person may consent
to ultra-hazardous, non-therapeutic research on himself").
250. Some prefer the term "proxy consent" because they believe true consent can
only be given to researchers by the embryos themselves. Casey & Adams, supra
note 116, at 112.
251. See id. at 112-15.
252. Id. at 118.
253. See Dolgin, supra note 66, at 129.
254. HEROLD, supra note 14, at 72-74 ("A decision conferring legal personhood
on an in-vitro embryo would compel a revising of Roe v. Wade and would pave the
way to the nationwide outlawing of abortion."); Brodsky, supra note 149, at 251-52
('This time, however, the controversy will not involve the liberty interests of
individual women, as addressed in Roe and Casey, but rather, what Roe and Casey
left open-namely, the liberty interests of the embryo against the health and safety
interests of those who might benefit from its sacrifice.").
255. See Brief for Petitioner-Appellant at 2, Mary Scott Doe v. Klein, No, 06-
55387, 2006 WL 2701381, *1-2 (9th Cir. July 31, 2006) (citing the district court's
dismissal of plaintiffs' claim for improper venue).
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B. The Adult, Embryonic, and Therapeutic Alike:
Permitting an Expansive Array of Stem Cell Research
While regulating the entire field of SCR, Connecticut's law
expressly expands the types of research eligible for public
monies. 256 Unlike the federal government's system for disbursing
research grants, Connecticut funds the development of new ESC
lines using a variety of techniques, including the extraction of new
stem cells from embryos provided by IVF clinics and the extraction
of new stem cells from embryos produced using therapeutic
cloning.257
1. Orphan Embryos: IVF Clinical Waste
To pro-research advocates, the process of extracting stem
cells from abandoned IVF embryos is justifiable. 25 8 IVF clinics
create these cells in furtherance of reproduction, not research, and
the cells are likely to be destroyed regardless. 259 The potential
research benefits of studying ]VF embryos are only afterthoughts
to their creation. Some believe research on IVF cells is more
ethically appropriate than producing, and then destroying,
embryos solely for experimentation. 260
Research opponents who categorize embryos as living beings
with the same human rights as viable fetuses remain unconvinced
by the they-are-going-to-die-anyway approach. To them, no
potential benefit can justify the destruction of embryos. "Who
among us has the right to decide that another human life is a
'spare' life, especially when that human life does not have the
chance to contest the decision?"261 These opponents argue that
"federal or state laws should . . . limit the number of human
embryos that may be cryopreserved in the IVF treatment process,
regulate the disposition of living and frozen human embryos, and
encourage embryo adoption over donation. '262 In fact, the federal
government, under the Bush Administration, has already
contributed over one million dollars toward embryo-adoption
256. CONN. GEN. STAT. § 19a-32e(c) (Supp. 2007).
257. CONN. GEN. STAT. § 19a-32d(d) (Supp. 2007).
258. See Charo, supra note 248, at 145-46.
259. Erik Parens, On the Ethics and Politics of Embryonic Stem Cell Research, in
THE HUMAN EMBRYONIC STEM CELL DEBATE: SCIENCE, ETHICS, AND PUBLIC POLICY
37, 43 (Suzanne Holland et al. eds., 2001).
260. JOHNSON & WILLIAMS, supra note 111, at 32.
261. Brodsky, supra note 149, at 239 (quoting Friar Kevin Fitzgerald, professor
at Georgetown University).




Nevertheless, it is flawed logic to equate potential life with
actualized life.264 This position assumes the potential for life will
successfully develop into a sustainable fetus. "It is preposterous to
define embryos as human life, because there is no way to
practically apply such a definition." 265 Scientists are not the only
ones adopting an amorphous definition of life. Religious leaders of
all faiths call to question the living status of an embryo existing
outside a woman's womb. 266
If anti-research advocates are truly concerned with the lives
or potential lives of embryos, they should also object to the
destruction and freezing of embryos in furtherance of IVF
treatments. "[I]t is difficult to tolerate the waste that accompanies
modern infertility care, its laboratories filled with frozen surplus
embryos that are no longer wanted by anyone." 267 In July 2004,
eighty-four percent of clinics admitted to still routinely destroying
leftover tissues. 268 Similarly, natural conception results in the
destruction of some fertilized embryos, 269 and modern, legal birth
control, such as the morning after pill, prevents embryos from
attaching to a woman's uterus. 270 The reality is that embryos will
continue to be destroyed regardless of ESCR.
Recognizing this, Connecticut's law provides specific
guidelines for the process of obtaining ESCs from IVF clinics.
First, the donors must provide voluntary informed consent waivers
before donating their tissue.271 Second, the statute criminalizes
263. HEROLD, supra note 14, at 126. "Adoption" is the preferred term used by
anti-research advocates to describe the process of implanting abandoned frozen
embryos into a surrogate mother. See generally Nightlight Christian Adoptions,
http://www.nightlight.org/snowflakeadoption.htm (last visited Nov. 9, 2007)
(discussing the Snowflakes Embryo Adoption Program). But see HEROLD, supra
note 14, at 126 ("[President Bush's] policy of promoting 'embryo adoption' is
deceptive because there is no realistic possibility of this happening on a large
enough scale to solve the 'embryo problem."').
264. HEROLD, supra note 14, at 138-39 (suggesting that at best, embryos possess
a conditional potential to become human life).
265. Langley & Blackston, supra note 88, at 203.
266. Childress, supra note 144, at 160; see also HEROLD, supra note 14, at 130-
34 ('The view that embryonic stem cell research is universally opposed by those
with strong religious beliefs is a major misconception.").
267. Charo, supra note 248, at 145; see also HEROLD, supra note 14, at 136 ("It's
hard to get around the fact that an absolutist view of the embryo is incompatible
with the IVF practices .... ").
268. HEROLD, supra note 14, at 36-37 (citation omitted).
269. Id. at 123-24 ("[I]n a woman's body, only 30 to 40 percent of embryos ever
create a successful pregnancy.").
270. Langley & Blackston, supra note 88, at 203.
271. CONN. GEN. STAT. § 19a-32d(c)(1) to (3) (Supp. 2007).
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monetary gain for the donation of cells. 272  These restrictions
should appease those concerned with the potential development of
a black market where donors provide reproductive tissue to clinics
not for IVF purposes but rather solely for the purpose of financial
gain. As for the other concerns, no regulation would be sufficient,
short of banning all IVF (which very few anti-research advocates
propose).
2. The "C" Word
Connecticut's law takes a progressive, informed approach to
cloning. It creates an important distinction between the
reproductive and therapeutic methods. 273 The statute prohibits
human cloning, which it defines as the process of "inducing or
permitting a replicate of a living human being's complete set of
genetic material to develop after gastrulation commences." 274 This
definition limits cloning to the creation of a duplicate human while
permitting therapeutic cloning, or "nuclear transfer," during the
embryo's gastrulation period.275 "Nuclear transfer" is defined as
"the replacement of the nucleus of a human egg with a nucleus
from another human cell. '276 While both techniques "rely upon
the creation of a five-day-old human embryo," their purposes and
outcomes differ significantly. 277 The statute's distinction between
the two allows Connecticut to recognize this country's hesitation
concerning human reproductive cloning while simultaneously
acknowledging the importance of therapeutic cloning for the
advancement of ESCR.
Using the "c" word to define both of these processes is
perhaps the biggest terminology blunder made by ESC
researchers. Unfortunately, scientists probably developed these
terms with little contemplation of the political ramifications. The
vast majority of Americans have not yet been properly informed of
272. § 19a-32d(c)(3) to (4).
273. § 19a-32d(a)(2), (5). Therapeutic cloning is sometimes referred to as
somatic nuclear transfer.
274. § 19a-32d(a)(2) to (5).
275. § 19a-32d(a)(2). The gastrulation period is then defined as "the process
immediately following the blastula state when the hollow ball of cells representing
the early embryo undergoes a complex and coordinated series of movements that
results in the formation of the three primary germ layers, the ectoderm, mesoderm
and endoderm." § 19a-32d(a)(3).
276. § 19a-32d(a)(5).
277. Cibelli, supra note 46, at A16; see also HEROLD, supra note 14, at 49
('Reproductive cloning is the creation of an exact genetic copy of an entire
organism."); supra text accompanying notes 40-47.
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the difference between reproductive and therapeutic cloning. 278
This is very problematic considering how socially unpopular the
word "cloning" is with mainstream America. 279  Perhaps
recognizing this problem, Connecticut wisely chose to label
therapeutic cloning as "nuclear transfer."280 This subtle definition
change may assist in the broader effort to differentiate between
these two techniques.
Regardless of the distinct differences between the two
techniques, anti-research activists still view therapeutic cloning as
a slippery slope, 28 1 and have begun to challenge some states'
acceptance of the technology in court. Surprisingly, they have not
yet filed suit in Connecticut. Litigation has occurred, however, in
California, Maryland, and Missouri. 28 2  Missourians Against
Human Cloning v. Carnahan2 3 tackled the cloning-definition
debate. The complaint challenged the definition of "cloning" found
in a proposal subsequently approved by Missourians in the 2006
elections. 28 4 Plaintiffs claimed that the definition was misleading
because it only banned reproductive and not therapeutic
cloning. 285
The real difference between these two very distinct
procedures, however, cannot be ignored. Generally speaking, most
scientists seeking to conduct therapeutic cloning have no interest
in reproducing a human being. 28 6 The purpose is largely to
overcome the immune rejection problems faced by stem cell
therapy recipients. 28 7 The definitions provided in the Connecticut
statute, much like the definitions found on the November 2006
ballot in Missouri, sufficiently draw this line, leaving the debate
278. See HEROLD, supra note 14, at 49 ("Unfortunately, right-to-life groups have
confused the public .... ").
279. Saad, supra note 6, at 7 (noting that eighty-six percent of Americans believe
that cloning is morally wrong).
280. § 19a-32d(a)(5).
281. Dolgin, supra note 66, at 148. "Once scientists get approval for creating,
experimenting [on,] and killing the smallest of cloned humans, their incessant push
for no moral boundaries will extend past the embryo state to cloned fetuses (unborn
babies), then onto newborns and beyond." HEROLD, supra note 14, at 106 (quoting
a Concerned Women for America poster).
282. HEROLD, supra note 14, at 72-73.
283. 190 S.W.3d 451 (Mo. Ct. App. 2006).
284. See id.
285. Id. at 453-54. In this case, the court avoided addressing the main
allegation of the complaint, holding plaintiffs failed to meet their burden of proving
that the language was "insufficient" and "unfair." Id. at 457.
286. See BELLOMO, supra note 42, at 135 (noting that "at present, researching. .
cloning to create human beings is shunned in the scientific community").
287. Supra text accompanying notes 40-47.
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surrounding the ethics of reproductive cloning for another day.
Even though such cloning distinctions have been made in
Connecticut, Missouri, and elsewhere, many cautious, research-
friendly states have continued to take a bright-line approach when
it comes to cloning by forbidding all forms. 28 8 Unfortunately, these
politically-conscious states are not going far enough to support
meaningful research. Without permitting therapeutic cloning in
their research schemes, these states are limiting scientists to
experimentation that is less likely to develop into usable
therapies. 289  Because of this, they risk falling behind
international researchers. Even though many countries also
restrict therapeutic cloning and instead rely on IVF clinic cells, 290
the countries at the forefront of research take a more expansive
research approach, much like Connecticut, and permit public
funding of this practice. 291
VI. The Miracle Cell: The Potential for ESCR Technology in
an Era of Inadequate Public Funding
Many studies show that the federal policy is at odds with
public opinion. When President Bush's policy was enacted in
2001, fifty-eight percent of Americans polled supported federal
funding of ESCR and only thirty percent opposed it.292 In June
2005, near the time the Connecticut bill was passed, a Gallop Poll
reported that sixty percent of Americans "find it morally
acceptable to destroy embryos in order to prevent suffering and
find cures for debilitating diseases such as diabetes, Alzheimer's
and Parkinson's." 293 Because Americans are slowly beginning to
288. See, e.g., The States Confront Stem Cells, supra note 164, at A18(L)
(pointing to Maryland's law allowing research on embryos obtained from IVF clinics
but not those created by therapeutic cloning). Other state leaders have
unsuccessfully attempted to ban cloning outright. Id. (citing Wisconsin Governor's
veto of a bill that would have made therapeutic cloning a criminal offense);
Massachusetts Allows Work on Embryo Stem Cells, supra note 166, at 8 (referring
to the Massachusetts State Legislature overriding the Governor's veto of a law
allowing therapeutic cloning).
289. Supra text accompanying notes 40-47.
290. Knowles, supra note 82, at 624 (citing the policies of Canada, Australia,
Spain, Finland, and the Netherlands).
291. Id. (citing the United Kingdom, Belgium, and China); see HEROLD, supra
note 14, at 203-19; Fowler, supra note 12, at 530-33. "[T]he United States has
steadily fallen behind several other countries, such as Britain, Israel, and
Singapore, that are rapidly moving ahead in the field." HEROLD, supra note 14, at
203.
292. Fowler, supra note 12, at 529 n.66 (citing an ABC poll conducted on
http://www.beliefnet.com in June 2001).
293. Editorial, Stemming Disease Top Priority, HARTFORD COURANT (Conn.),
Law and Inequality
realize the important benefits to be gained from this research, the
President's policy should be reconsidered.
The President . . . like all Americans, [is] entitled to . . . [his]
own personal faith and vision. But should the day come when
that vision is shown to be too narrow to accommodate the
needs of research on behalf of all Americans, one hopes that
the vision may broaden to encompass the diversity of all
human experience and all human faiths. 294
The increasing public support for the technology only further
legitimizes state laws like Connecticut's that seek to aid citizens in
ways that the federal government currently does not.
Unfortunately, over 3,000 Americans die daily from the cell-based
conditions that embryonic stem cell research may one day cure. 295
Although cautious about how much work must still be done,
scientists project many diseases, disabilities, and ailments could
benefit from ESC therapies, including Leukemia, immune
deficiencies, diabetes, liver disease, cardiovascular disease,
neurological disorders, Alzheimer's disease, Parkinson's disease,
spinal cord trauma, and cancer. 296
A common argument against research is that the government
should not spend money to advance the technologies because the
benefits will not be realized for many years. 297 Such a statement
is hardly deserving of a response. All responsible scientific
endeavors take time, but this is no reason to discourage public
support of research. To date, we do not have a cure for AIDS, but
that is hardly a reason to stop searching for one. Even if ESC
therapies are not developed in time for those currently in need of
treatment, science should press on in hope of relieving the
suffering of future patients. Critics should not give up too soon on
such a rapidly advancing technology. After all, human stem cells
were only first extracted from embryos in 1998, less than ten years
ago and with little government funding. 298 In this short amount of
time, many promising results have been produced in animal
experiments, 299 and scientists in this country are working
May 26, 2005, at A12.
294. Charo, supra note 248, at 149.
295. HEROLD, supra note 14, at 137.
296. PANNO, supra note 3, at 34-49; VIEGAS, supra note 3, at 56; Crockin, supra
note 27, at 609.
297. See, e.g., Response Ad to Michael J. Fox, available at
http://www.youtube.com/watch?v-nguJQ-dRPXw (last visited Oct. 28, 2007)
("Californians ... admit that there won't be any cures for at least fifteen years. ...
[B]eware of loopholes, Missourians will pay. Don't be tricked.").
298. HEROLD, supra note 14, at 47. By contrast, scientists have been working
with adult stem cells for over fifty years. Id.
299. See, e.g., VIEGAS, supra note 3, at 48 (citing a study in which researchers
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diligently to expand their research into usable treatments for
humans. For example, at Harvard University and the University
of California, San Francisco, scientists are developing technologies
to treat diabetes and Parkinson's. 300 The only way to find cures is
to continue on with research. Hopefully, with Connecticut
research institutions like Yale University, Wesleyan University,
and the University of Connecticut now on board and financially
equipped, further advancements will soon be realized.
Conclusion
With ESCR quickly evolving and popular opinion of the
technology steadily improving, states should re-evaluate their
anti-research positions. In the absence of comprehensive federal
guidance, states can look to Connecticut's statute as a model when
developing new research policies. Connecticut's concise
definitions, research-friendly policies, generous funding, and
procedural oversight of experiments all assist in the advancement
of the scientific integrity of both Connecticut and the United
States. As Professor Cibelli, head of the Cellular Reprogramming
Laboratory at Michigan State University, exclaims: "[W]ake up
America! This is not about Republican vs. Democrat, pro-life vs.
pro-choice, scientists vs. intellectuals, embryonic stem cells vs.
adult stem cells. It is about compassion for those suffering. It is
about millions of patients around the world that deserve better
quality of life." 30 1
restored movement in paralyzed rats).
300. Hathaway, supra note 220, at B1.
301. Cibelli, supra note 46, at A16.
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